Decoding the complexities of biopsies for KRAS+ NSCLC, join Dr. Jia Luo, a prominent Medical Oncologist at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard, in this informative session from the 2022 Targeted Therapies Forum. With an in-depth look into KRAS Mutated NSCLC management, Dr. Luo specifically shines a light on the various biopsy types crucial for KRAS diagnosis.
Heartfelt gratitude to our esteemed sponsors for their unwavering support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech.
For a broader spectrum of resources and insights in the realm of oncology, visit http://cancerGRACE.org/. Join our vibrant community and engage in meaningful discussions at https://cancergrace.org/forum.